Benchtop Analyzer Runs Chemistries, Immunoassays and Hematology in Single Device

By LabMedica International staff writers
Posted on 03 Dec 2025

Routine blood tests remain dependent on off-site laboratories, resulting in delays, higher costs, and logistical barriers in decentralized care settings. Now, a new multimodal diagnostic solution delivers lab-quality results from a small blood sample in minutes, simplifying workflows and expanding access to timely testing.

Truvian Health (San Diego, CA, USA) has developed the TruVerus benchtop analyzer that is capable of running clinical chemistries, immunoassays, and hematology assays on a single platform. Until now, no single on-site platform could run clinical chemistry, immunoassays, and hematology in a single device. By uniting three major testing modalities in one device, TruVerus represents a significant shift toward decentralized diagnostics.


Image: The US FDA has cleared TruVerus, the first multimodal benchtop blood analyzer for rapid, decentralized testing (Photo courtesy of Truvian Health)

TruVerus integrates patented technologies and proprietary dry-reagent architecture to deliver comprehensive results from a fraction of the blood required by traditional testing. The compact, plug-and-play instrument provides automated, lab-accurate results within minutes and is designed to eliminate send-outs while reducing the complexity of routine diagnostics.

The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for TruVerus. The system’s initial clearance includes a kidney health panel measuring creatinine, blood urea nitrogen (BUN), and eGFR. Each test run uses a disposable disc and a support pack that contains all necessary reagents for multimodal analysis. Additional assay panels have already been submitted for FDA review as part of the company’s staged-clearance strategy to build a full menu of routine blood tests on a single, automated benchtop platform.

“Truvian is poised to disrupt the diagnostics industry by creating a future where full lab testing is decentralized, improving access, and providing results in minutes, while using only a fraction of the blood needed for other routine blood testing,” said Michael J. Mina, MD, Ph.D., one of the leading diagnostics and industry experts and member of Truvian’s scientific advisory board. “This boldly empowers providers to deliver faster, more informed, and ultimately, more equitable care.”

Related Link
Truvian Health


Latest Molecular Diagnostics News